Serum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer

Andrew C. McCoy, Beth Kliethermes, Ke Zhang, Wenyi Qin, Robert P. Sticca, Michael Bouton, Edward R. Sauter
In: BMC Research Notes · 2011 · vol. 4(1) , pp. 152 · doi:10.1186/1756-0500-4-152 · PMID:21615907 · W2126195263
article OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher

Abstract

BACKGROUND: In preclinical studies, müllerian inhibiting substance (MIS) has a protective affect against breast cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or precancerous lesions. Blood from 30 premenopausal women was collected and serum extracted prior to their undergoing breast biopsy to assess a suspicious lesion found on imaging or physical examination. Based on biopsy results, the serum specimens were grouped as cancer (invasive or ductal carcinoma in situ), precancer (atypical hyperplasia or lobular carcinoma in situ), or benign. FINDINGS: Serum from women with cancer and precancer (p = .0009) had lower MIS levels than serum from women with benign disease. CONCLUSION: Our findings provide preliminary evidence for MIS being associated with current breast cancer risk, which should be validated in a larger population.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (10)

SciLite annotations

organisms 3
homo heidelbergensis rodents noordeloos 2009062
chemicals 1
glycoprotein

Source provenance

openalex
last seen: 2026-05-11T06:08:11.709964+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK